Drugs of the 21st century: Telithromycin (HMR 3647) - The first ketolide

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 3, 2003, Pages 497-511

  Ackermann, Grit ^a   Rodloff, Arne C ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

New antimicrobials; Resistance; Telithromycin

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEFUROXIME; CHLORAMPHENICOL; CISAPRIDE; CLARITHROMYCIN; CLINDAMYCIN; CYCLOSPORIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; ERYTHROMYCIN DERIVATIVE; ERYTHRONOLIDE A; ITRACONAZOLE; JOSAMYCIN; KETOCONAZOLE; KETOLIDE; LINCOSAMIDE DERIVATIVE; MACROLIDE; METRONIDAZOLE; MIDAZOLAM; PENICILLIN G; PUROMYCIN; RAPAMYCIN; ROXITHROMYCIN; SIMVASTATIN; SULFADIAZINE; TACROLIMUS; TELITHROMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ABDOMINAL ABSCESS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTERIAL PNEUMONIA; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SALIVA LEVEL; DRUG TOLERANCE; DRUG TRANSPORT; DRUG UPTAKE; GRAM NEGATIVE INFECTION; HEADACHE; HUMAN; LEPROSY; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; PERITONITIS; PHARYNGITIS; RESPIRATORY TRACT INFECTION; REVIEW; STRUCTURE ACTIVITY RELATION; TOXOPLASMOSIS; VERTIGO; VOMITING;

ANIMALS; ANTI-BACTERIAL AGENTS; BASE SEQUENCE; CLINICAL TRIALS; DRUG RESISTANCE, BACTERIAL; HUMANS; KETOLIDES; MACROLIDES; MOLECULAR SEQUENCE DATA; RESPIRATORY TRACT INFECTIONS; RNA, BACTERIAL;

EID: 0037342872     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg123     Document Type: Review

References (104)

1. Blondeau, J. M. (1999). Expanded activity and utility of the new fluoroquinolones: a review. Clinical Therapy 21, 3-40; discussion 1-2.
2. Müller, M. & Schimz, K.-L. (1999). Oxazolidinones: a novel class of antibiotics. Cellular and Molecular Life Sciences 56, 280-5.
3. Felmingham, D., Reinert, R. R., Hirakata, Y. & Rodloff, A. C. (2002). Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide telithromycin. Journal of Antimicrobial Chemotherapy 50, Suppl. S1, 25-37.
4. Appelbaum, P. C. (2002). Resistance among Streptococcus pneumoniae: implications for drug selection. Clinical Infectious Diseases 34, 1613-20.
5. Cantón, R., Loza, E., Morosini, M. I. & Baquero, F. (2002). Antimicrobial resistance amongst isolates of Streptococcus pyogenes and Staphylococcus aureus in the PROTEKT antimicrobial surveillance programme during 1999-2000. Journal of Antimicrobial Chemotherapy 50, Suppl. S1, 9-24.
6. Kresken, M., Hafner, D. & die Studiengruppe. (2000). Resistenzsituation bei klinisch wichtigen Infektionserregern gegenüber Chemotherapeutika in Mitteleuropa. Chemotherapie Journal 9, 51-86.
7. McGuire, J. M., Bunch, P. L. & Anderson, R. C. (1952). Ilotycin, a new antibiotic. Antibiotics and Chemotherapy 2, 281-3.
8. Jones, W. R., Nichols, R. L. & Finland, M. (1956). Development of resistance and cross-resistance in vitro to erythromycin, carbomycin, spiramycin, oleandromycin and streptogramin. Proceedings of the Society for Experimental Biology and Medicine 93, 388-93.
9. Douthwaite, S. & Champney, W. S. (2001). Structures of ketolides and macrolides determine their mode of interaction with the ribosomal target site. Journal of Antimicrobial Chemotherapy 48, 1-8.
10. Bryskier, A. (2000). Ketolides - telithromycin, an example of a new class of antibacterial agents. Clinical Microbiology and Infection 6, 661-9.
11. Douthwaite, S. (2001). Structure-activity relationships of ketolides vs. macrolides. Clinical Microbiology and Infection 7, Suppl. 3, 11-7.
12. Cundliff, E. (1990). Recognition sites for antibiotics within rRNA. In The Ribosome: Structure, Function and Evolution (Hill, W. E., Dahlberg, A., Garrett, R. A., Moore, P. B., Schlesinger, D. & Warner, J. R., Eds), pp. 479-90. American Society for Microbiology Press, Washington, DC, USA.
13. Vester, B. & Douthwaite, S. (2001). Macrolide resistance conferred by base substitution in 23S rRNA. Antimicrobial Agents and Chemotherapy 45, 1-12.
14. Ban, N., Nissen, P., Hansen, J., Moore, P. B. & Steitz, T. A. (2000). The complete atomic structure of the large ribosomal subunit at 2.4 Å resolution. Science 289, 905-20.
15. Nissen, P., Hansen, J., Ban, N., Moore, P. B. & Stitz, T. A. (2000). The structural basis of ribosome activity in peptide bond synthesis. Science 289, 920-30.
16. Hansen, L. H., Mauvais, P. & Douthwaite, S. (1999). The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA. Molecular Microbiology 31, 623-31.
17. Barry, A. L., Fuchs, P. C. & Brown, S. D. (2001). Relative potency of telithromycin, azithromycin and erythromycin against recent clinical isolates of Gram-positive cocci. European Journal of Clinical Microbiology and Infectious Diseases 20, 494-7.
18. Barry, A. L., Fuchs, P. C. & Brown, S. D. (1998). Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin) and a lincosamide (clindamycin). Antimicrobial Agents and Chemotherapy 42, 945-6.
19. Mandell, G. L. & Coleman, E. J. (2000). Activities of antimicrobial agents against intracellular pneumococci. Antimicrobial Agents and Chemotherapy 44, 2561-3.
20. Morosini, M-I., Canton, R., Loza, E., Negri, M.-C., Galan, J.-C., Almaraz, F. et al. (2001). In vitro activity of telithromycin against Spanish Streptococcus pneumoniae isolates with characterized macrolide resistance. Antimicrobial Agents and Chemotherapy 45, 2427-31.
21. Bemer-Melchior, P., Juvin, M. E., Tassin, S., Bryskier, A., Schito, G. C. & Drugeon, H. B. (2000). In vitro activity of the new ketolide telithromycin compared with those of macrolides against Streptococcus pyogenes: influence of resistance mechanisms and methodological factors. Antimicrobial Agents and Chemotherapy 44, 2999-3002.
22. Giovanetti, E., Montanari, M. P., Mingoia, M. & Varaldo, P. E. (1999). Phenotypes and genotypes of erythromycin-resistant Streptococcus pyogenes strains in Italy and heterogeneity of inducible strains. Antimicrobial Agents and Chemotherapy 43, 1935-40.
23. Hoellmann, D. B., Lin, G., Jacobs, M. R. & Appelbaum, P. C. (1999). Activity of HMR 3647 compared to those of six compounds against 235 strains of Enterococcus faecalis. Antimicrobial Agents and Chemotherapy 43, 166-8.
24. Hoppe, J. E. & Bryskier, A. (1998). In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine). Antimicrobial Agents and Chemotherapy 42, 965-6.
25. Engler, K. H., Warner, M. & George, R. C. (2001). In vitro activity of ketolides HMR 3004 and HMR 3647 and seven other antimicrobial agents against Corynebacterium diphtheriae. Journal of Antimicrobial Chemotherapy 47, 27-31.
26. Martinez-Martinez, L., Pascual, A., Suarez, A. I. & Perea, E. J. (1998). In vitro activity of ketolide HMR 3647, macrolides, and clindamycin against coryneform bacteria. Antimicrobial Agents and Chemotherapy 42, 3290-2.
27. Edelstein, P. H. & Edelstein, M. A. C. (1999). In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in Guinea pigs, and use of the drug to treat Guinea pigs with Legionella pneumophila pneumonia. Antimicrobial Agents and Chemotherapy 43, 90-5.
28. Gustafsson, I., Hjelm, E. & Cars, O. (2000). In vitro pharmacodynamics of the new ketolides HMR 3004 and HMR 3647 (telithromycin) against Chlamydia pneumoniae. Antimicrobial Agents and Chemotherapy 44, 1846-9.
29. Roblin, P. M. & Hammerschlag, M. R. (1998). In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae. Antimicrobial Agents and Chemotherapy 42, 1515-6.
30. Bebear, C. M., Renaudin, H., Bryskier, A. & Bebear, C. (2000). Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas. Antimicrobial Agents and Chemotherapy 44, 1980-2.
31. Rolain, J.-M., Maurin, M., Bryskier, A. & Raoult, D. (2000). In vitro activities of telithromycin (HMR 3647) against Rickettsia rickettsii, Rickettsia conorii, Rickettsia africae, Rickettsia typhi, Rickettsia prowazekii, Coxiella burnetii, Bartonella henselae, Bartonella quintana, Bartonella bacilliformis, and Ehrlichia chaffensis. Antimicrobial Agents and Chemotherapy 44, 1391-3.
32. Saez-Nieto, J. A. & Vazquez, J. A. (1999). In vitro activities of ketolides HMR 3647 and HMR 3004, levofloxacin, and other quinolones and macrolides against Neisseria spp. and Moraxella catarrhalis. Antimicrobial Agents and Chemotherapy 43, 983-4.
33. Felmingham, D. (2001). Microbiological profile of telithromycin, the first ketolide antimicrobial. Clinical Microbiology and Infection 7, Suppl. 3, 2-10.
34. Rastogi, N., Goh, K. S., Berchel, M. & Bryskier, A. (2000). In vitro activities of the ketolide telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at pHs 6.8 and 7.4. Antimicrobial Agents and Chemotherapy 44, 2848-52.
35. Gustafsson, I., Engstrand, L. & Cars, O. (2001). In vitro pharmacodynamic studies of activities of ketolides HMR 3004 and HMR 3647 (telithromycin) against extracellular or intracellular Helicobacter pylori. Antimicrobial Agents and Chemotherapy 45, 353-5.
36. Ackermann, G., Schaumann, R., Pless, B., Claros, M. C. & Rodloff, A. C. (2000). In vitro activity of telithromycin (HMR 3647) and seven other antimicrobial agents against anaerobic bacteria. Journal of Antimicrobial Chemotherapy 46, 115-9.
37. Bryskier, A. & Denis, A. (2002). Ketolides: novel antibacterial agents designed to overcome resistance to erythromycin A within Gram-positive cocci. In Macrolide Antibiotics (Schönfeld, W. & Kirst, H. A., Eds), pp. 97-140. Birkhäuser Verlag, Basel, Switzerland.
38. Leclercq, R. & Courvalin, P. (1991). Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrobial Agents and Chemotherapy 35, 1267-72.
39. Seppälä, H., Skurnik, M., Soini, H., Roberts, M. C. & Huovinen, P. (1998). A novel erythromycin resistance methylase gene (ermTR) in Streptococcus pyogenes. Antimicrobial Agents and Chemotherapy 42, 257-62.
40. Douthwaite, S., Hansen, L. H. & Mauvais, P. (2000). Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA. Molecular Microbiology 36, 183-93.
41. Xiong, L., Shah, S., Mauvais, P. & Mankin, A. S. (1999). A ketolide resistance mutation in domain II of 23S rRNA reveals the proximity of hairpin 35 to the peptidyl transferase centre. Molecular Microbiology 31, 633-9.
42. Liu, M. & Douthwaite, S. (2002). Activity of the ketolide telithromycin is refractory to erm monomethylation of bacterial rRNA. Antimicrobial Agents and Chemotherapy 46, 1629-33.
43. Davies, T. A., Dewasse, B. E., Jacobs, M. R. & Appelbaum, P. C. (2000). In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 44, 414-7.
44. Taidt-Kamradt, A. G., Reinert, R. R., Al-Lahham, A., Low, D. E. & Sutcliffe, J. A. (2001). High-level ketolide-resistant streptococci. In Program and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2001. Abstract C1-18113, p. 101. American Society for Microbiology, Washington, DC, USA.
45. Garza-Ramos, G., Xiong, L., Zhong, P. & Mankin, A. (2001). Binding site of macrolide antibiotics on the ribosome: new resistance mutation identifies a specific interaction of ketolides with rRNA. Journal of Bacteriology 183, 6898-907.
46. B resistance phenotype. Journal of Antimicrobial Chemotherapy 40, 85-90.
47. Schmitz, F. J., Petridou, J., Jagusch, H., Astfalk, N., Scheuring, S. & Schwarz, S. (2002). Molecular characterization of ketolide-resistant erm(A)-carrying Staphylococcus aureus isolates selected in vitro by telithromycin, ABT-773, quinupristin and clindamycin. Journal of Antimicrobial Chemotherapy 49, 611-7.
48. Clancy, J., Petitpas, J., Dib-Hajj, F., Yuan, W., Cronan, M., Kamath, V. et al. (1996). Molecular cloning and functional analysis of a novel macrolide resistance determinant, mefA, from Streptococcus pyogenes. Molecular Microbiology 22, 867-79.
49. Sutcliffe, J., Tait-Kamradt, A. & Wondrack, L. (1996). Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrobial Agents and Chemotherapy 40, 1817-24.
50. Gay, K. & Stephens, D. S. (2001). Structure and dissemination of a chromosomal insertion element encoding macrolide efflux in Streptococcus pneumoniae. Journal of Infectious Diseases 184, 56-65.
51. Nakajima, Y. (1999). Mechanisms of bacterial resistance to macrolide antibiotics. Journal of Infection and Chemotherapy 5, 61-74.
52. Leclercq, R. (2002). Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clinical Infectious Diseases 34, 482-92.
53. Tai-Kamradt, A., Davies, T., Cronan, M., Jacobs, M. R., Appelbaum, P. C. & Sutcliffe, J. (2000). Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrobial Agents and Chemotherapy 44, 2118-25.
54. Bonnefoy, A., Guitton, M., Delachaume, C., Le Priol, P. & Girard, A.-M. (2001). In vivo efficacy of the new ketolide telithromycin (HMR 3647) in murine infection models. Antimicrobial Agents and Chemotherapy 45, 1688-92.
55. Nichterlein, T., Kretschmar, M. & Hof, H. (1999). The ketolide antibiotic HMR 3647, a candidate substance for the treatment of systemic and intracerebral infections with Listeria monocytogenes. Zentralblatt für Bakteriologie 289, 155-64.
56. Thadepalli, H., Chuah, S. K., Qazi, S., Thadepalli, F. & Gollapudi, S. V. (2001). Bacteroides fragilis-induced intra-abdominal abscess in an experimental model treated with telithromycin (HMR 3647). Chemotherapy 47, 43-9.
57. Singh, K. V., Zscheck, K. K. & Murray, B. E. (2000). Efficacy of telithromycin (HMR 3647) against enterococci in a mouse peritonitis model. Antimicrobial Agents and Chemotherapy 44, 3434-7.
58. Araujo, F. G., Khan, A. A., Bryskier, A. & Remington, J. S. (1998). Use of ketolides in combination with other drugs to treat experimental toxoplasmosis. Journal of Antimicrobial Chemotherapy 42, 665-7.
59. Piper, K. E., Rouse, M. S., Steckelberg, J. M., Wilson, W. R. & Patel, R. (1999). Ketolide treatment of Haemophilus influenzae experimental pneumonia. Antimicrobial Agents and Chemotherapy 43, 708-10.
60. Bentoucha, A., Robert, J., Dega, H., Lounis, N., Jarlier, V. & Grosset, J. (2001). Activities of new macrolides and new fluoroquinolones against Mycobacterium ulcerans infection in mice. In Program and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2001. Abstract B-1376, p. 64. American Society for Microbiology, Washington, DC, USA.
61. Mattoes, H.M, Tessier, P. R., Nightingale, C. H. & Nicolau, D. P. (2001). Bactericidal activity of telithromycin against macrolide-resistant (erm(B), mef(A)), and fluoroquinolone-resistant Streptococcus pneumoniae in a murine thigh infection model. In Program and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2001. Abstract B-1656, p. 69. American Society for Microbiology, Washington, DC, USA.
62. Törmäkagangas, L., Ben David, D., Bryskier, A., Leinonen, M. & Saikku, P. (2001). Experimental mouse model for Chlamydia pneumoniae (Cpn) infection: effect of ketolide treatment on the chronic infection. In Program and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2001. Abstract B-1363, p. 61. American Society for Microbiology, Washington, DC, USA.
63. Delachaume, C., Steier, V., Bonnefoy, A., Hodgson, J. & Levasseur, P. (2001). Efficacy of telithromycin in an experimental pneumonia in mice caused by Mycoplasma pneumoniae. In Program and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2001. Abstract B-1000, p. 56. American Society for Microbiology, Washington, DC, USA.
64. Craig, W. A. & Andes, D. (2001). Pattern of bactericidal activity with telithromycin against erythromycin-resistant Streptococcus pneumoniae (SP) in the murine thigh infection model. In Program and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2001. Abstract A-2089, p. 34. American Society for Microbiology, Washington, DC, USA.
65. Fujikawa, T., Miyazaki, S., Ishii, Y., Furuya, N., Ohno, A., Matsumoto, T. et al. (2001). The in vivo activities of ABT-773 in mouse models of respiratory tract infection due to Streptococcus pneumoniae and Haemophilus influenzae. In Program and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2001. Abstract B-993, p. 55. American Society for Microbiology, Washington, DC, USA.
66. Consigny, S., Bentoucha, A., Bonnafous, P., Grosset, J. & Baohong, J. (2000). Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice. Antimicrobial Agents and Chemotherapy 44, 2919-21.
67. Piroth, L., Desbiolles, N., Mateo-Ponce, V., Martin, L., Lequeu, C., Charles, P.-E. et al. (2001). HMR 3647 human-like treatment of experimental pneumonia due to penicillin-resistant and erythromycin-resistant Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 47, 33-42.
68. Buchanan, P., McNeil, D., Tady, D., Andrade, C. & Leroy, B. (2001). A 5-day course of telithromycin, the first ketolide antibacterial, is as effective as 10 days cefuroxime axetil in the treatment of acute maxillary sinusitis. In Program and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2001. Abstract L-910, p. 461. American Society for Microbiology, Washington, DC, USA.
69. Van Rensburg, D. J., Matthews, P. A., Tady, D., Zuberbuhler, G. A. & Leroy, B. (2001). Efficacy of the first ketolide antibacterial, telithromycin, in the treatment of adult patients with community-acquired pneumonia in S. Africa. In Program and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2001. Abstract L-858, p. 449. American Society for Microbiology, Washington, DC, USA.
70. Aubier, M., Baz, M., Rangaraju, M. & Leroy, B. (2001). Telithromycin is highly effective in the treatment of community-acquired respiratory tract infections caused by Streptococcus pneumoniae with reduced penicillin and/or macrolide susceptibility. In Program and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2001. Abstract L-860, p. 450. American Society for Microbiology, Washington, DC, USA.
71. Hagberg, L., Pullman, J., Rangaraju, M. & Leroy, B. (2001). Telithromycin is effective in the treatment of pneumococcal bacteraemia associated with community-acquired pneumonia. In Program and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2001. Abstract L-861, p. 450. American Society for Microbiology, Washington, DC, USA.
72. Dunbar, L., Hagberg, L., Rangaraju, M. & Leroy, B. (2001). Seven to 10-day therapy with telithromycin, the first ketolide antimicrobial, is effective in community-acquired pneumonia caused by atypical and intracellular pathogens. In Program and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2001. Abstract L-859, p. 449. American Society for Microbiology, Washington, DC, USA.
73. Van Rensburg, D., Moola, S., Hagberg, L, Rangaraju, M. & Leroy, B. (2001). Oral telithromycin for 7-10 days is as effective as standard comparators for the treatment of community-acquired pneumonia. In Program and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2001. Abstract L-862, p. 450. American Society for Microbiology, Washington, DC, USA.
74. Roos, K., Tellier, G., Baz, M., Rangaraju, M. & Leroy, B. (2001). Five-day therapy with the new ketolide telithromycin is as effective as standard 10-day comparators in the treatment of acute maxillary sinusitis. In Program and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2001. Abstract L-909, p. 461. American Society for Microbiology, Washington, DC, USA.
75. Roos, K., Brunswig-Pitschner, C., Kostrica, R., Pietola, M., Leroy, B., Rangaraju, M. et al. (2002). Efficacy and tolerability of once-daily therapy with telithromycin for 5 or 10 days for the treatment of acute maxillary sinusitis. Chemotherapy 48, 100-8.
76. Norrby, S. R., Quinn, J., Rangaraju, M. & Leroy, B. (2001). Five-day therapy with telithromycin, a novel ketolide antimicrobial, is as effective as 10-day comparators for the treatment of tonsillopharyngitis. In Program and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2001. Abstract L-915, p. 462. American Society for Microbiology, Washington, DC, USA.
77. Zervos, M., Aubier, M., Rangaraju, M. & Leroy, B. (2001). Five-day telithromycin, a new ketolide, is as effective as standard 10-day comparators in the treatment of acute exacerbation of chronic bronchitis. In Program and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2001. Abstract L-916, p. 462. American Society for Microbiology, Washington, DC, USA.
78. Fogarty, C., Patel, T. C., Galbraith, H., Zuberbuhler, G. A. & Leroy, B. (2001). Efficacy of the first ketolide antibacterial, telithromycin, in the treatment of community-acquired pneumonia caused by Streptococcus pneumoniae. In Program and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2001. Abstract L-857, p. 449. American Society for Microbiology, Washington, DC, USA.
79. Bermudez, L. E., Inderlied, C. B., Kolonoski, P., Wu, M., Aralar, P. & Young, L. S. (2001). Telithromycin is active against Mycobacterium avium in mice despite lacking significant activity in standard in vitro and macrophage assays and is associated with low frequency of resistance during treatment. Antimicrobial Agents and Chemotherapy 45, 2210-4.
80. Carbon, C., Moola, S., Velancsis, I., Leroy, B., Rangaraju, M. & Decosta, P. (2000). Telithromycin (HMR 3647), a new once-daily ketolide antimicrobial, provides effective treatment of community-acquired pneumonia. In Program and Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 2000. Abstract 2245, p. 490. American Society for Microbiology, Washington, DC, USA.
81. Hagberg, L., Torres, A., Van Rensburg, D. J., Leroy, B., Rangaraju, M. & Ruuth, E. (2000). Efficacy and tolerability of telithromycin (HMR 3647) vs high-dose amoxicillin in the treatment of community-acquired pneumonia. In Program and Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 2000. Abstract 2244, p. 490. American Society for Microbiology, Washington, DC, USA.
82. Pullman, J., Champlin, J., Leroy, B. & Sidarous, E. (2000). Oral telithromycin (HMR 3647) 800 mg once daily for 7-10 days is well tolerated and as effective as oral trovafloxacin 200 mg once daily in community acquired pneumonia (CAP). In Program and Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 2000. Abstract 2230, p. 472. American Society for Microbiology, Washington, DC, USA.
83. Tellier, G., Hassman, J., Leroy, B., Sidarous, E. & Youngblood, D. (2000). Oral telithromycin (HMR 3647) 800 mg once-daily is well tolerated and as effective as oral clarithromycin 500 mg twice-daily in community-acquired pneumonia (CAP) in adults. In Program and Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 2000. Abstract 2227, p. 471. American Society for Microbiology, Washington, DC, USA.
84. Shain, C. S. & Amsden, G. W. (2002). Telithromycin: the first of the ketolides. Annals of Pharmacotherapy 36, 452-64.
85. Johnson, A. P. (2001). Telithromycin. Current Opinion in Investigational Drugs 2, 1691-701.
86. Drusano, G. (2001). Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin. Clinical Microbiology and Infection 7, Suppl. 3, 24-9.
87. Namour, F., Wessels, D. H., Pascual, M. H., Reynolds, D., Sultan, E. & Lenfant, B. (2001). Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses. Antimicrobial Agents and Chemotherapy 45, 170-5.
88. Muller-Serieys, C., Soler, P., Cantalloube, C., Lemaitre, F., Gia, H. P., Brunner, F. et al. (2001). Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647). Antimicrobial Agents and Chemotherapy 45, 3104-8.
89. Dubois, J. & St-Pierre, C. (2000). Telithromycin comparative bactericidal activity and postantibiotic effect (PAE) against respiratory pathogens (abstract WeP96). Clinical Microbiology and Infection 6, Suppl. 1, 85.
90. Boswell, F. J., Andrews, J. M. & Wise, R. (1998). Pharmacodynamic properties of HMR 3647, a novel ketolide, on respiratory pathogens, enterococci and Bacteroides fragilis demonstrated by studies of time-kill kinetics and postantibiotic effect. Journal of Antimicrobial Chemotherapy 41, 149-53.
91. Agouridas, C., Bonnefoy, A. & Chantot, J. F. (1998). In vivo antibacterial activity of HMR 3647, a novel ketolide highly active against respiratory pathogens. In Fourth International Conference on the Macrolides, Azalides, Streptogramins and Ketolides, Barcelona, Spain, 1998. Abstract 1.11. ICMAS, Atlanta, GA, USA.
92. Munckhof, W. J., Borlace, G. & Turndridge, J. D. (2000). Postantibiotic suppression of growth of erythromycin A-susceptible and -resistant Gram-positive bacteria by the ketolides telithromycin (HMR 3647) and HMR 3004. Antimicrobial Agents and Chemotherapy 44, 1749-53.
93. Champney, W. S. & Tober, C. L. (1998). Inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells by 11 different ketolide antibiotics. Current Microbiology 37, 418-25.
94. Champney, W. S. & Tober, C. L. (2001). Structure-activity relationships for six ketolide antibiotics. Current Microbiology 42, 203-10.
95. Bryskier, A., Agouridas, C. & Chantot, J. F. (2000). Ketolide: novel antibacterial agent designed to overcome erythromycin A resistance. In New Considerations for Macrolides, Streptogramin and Ketolides (Zinner, S. H., Young, L. S., Acar, J. F. & Oritz-Neu, C., Eds), pp. 79-102. Marcel Dekker, New York, NY, USA.
96. Vazifeh, D., Bryskier, A. & Labro, M. T. (1998). Interactions between HMR 3647, a new ketolide, and human polymorphonuclear neutrophils. Antimicrobial Agents and Chemotherapy 44, 1944-51.
97. Pascual, A., Ballesta, S., Garcia, I. & Perea, E. J. (2001). Uptake and intracellular activity of ketolide HMR 3647 in human phagocytic and non-phagocytic cells. Clinical Microbiology and Infection 7, 65-9.
98. Khair, O. A., Andrews, J. M., Honeybourne, D., Jevons, G., Vacheron, F. & Wise, R. (2001). Lung concentrations of telithromycin after oral dosing. Journal of Antimicrobial Chemotherapy 47, 837-40.
99. Aventis Pharma. (2002). Fachinformation Ketek 400 mg Filmtabletten Bundesverband der Pharmazeutischen Industrie e.V.; Fachinfo-Service, Aulendorf, Germany.
100. Edlund, C., Alvan, G., Barkholt, L., Vacheron, F. & Nord, C. E. (2000). Pharmacokinetics and comparative effects of telithromycin (HMR 3647) and clarithromycin on the oropharyngeal and intestinal microflora. Journal of Antimicrobial Chemotherapy 46, 741-9.
101. Edlund, C., Lode, H. & Nord, C. (2001). Clinafloxacin, linezolid and telithromycin can select for resistant bacteria in the human intestinal microflora. In Program and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2001. Abstract C2-1866, p. 137. American Society for Microbiology, Washington, DC, USA.
102. Muller-Serieys, C., Delatour, F., Lemaitre, F., Poirier, I., Panhard, X., Tchimichkian, F. et al. (2001). Effects of oral telithromycin versus amoxicillin/clavulanic acid (AMX/CA) on the intestinal, skin and oropharyngeal microflora of healthy volunteers. In Program and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2001. Abstract A-637, p. 20. American Society for Microbiology, Washington, DC, USA.
103. Barry, A. L., Fuchs, P. C. & Brown, S. D. (2001). Interpretive criteria and quality control parameters for telithromycin disc diffusion susceptibility tests. Journal of Antimicrobial Chemotherapy 48, 121-5.
104. Nagay, K., Davies, T. A., Ednie, L. M., Bryskier, A., Palavecino, E., Jacobs, M. R. et al. (2001). Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivate RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or-resistant Streptococcus pneumoniae and Streptococcus pyogenes. Antimicrobial Agents and Chemotherapy 45, 3242-5.